CluePoints Wins ENTENTE Life Science Investment Forum Award

By October 30, 2014 News No Comments

10-30-14

Win marks second award for CluePoints this month

9 December 2014

Cambridge, MA – CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has announced that it has won a European Venture Contest award.  The award program, which is part of the European Venture Summit, acknowledged CluePoints for its Central Statistical Monitoring (CSM) solution that employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data. The win represents the second industry award that CluePoints has secured this month after the company’s risk-based monitoring solution was also recognized by the Scrip Awards.

Each year over 800 start-ups enter the European Venture Contest, which hosts qualifying events across major European cities throughout the year. The top quartile from each of the qualifiers continue to the major end-of-year event, where 120 finalists are reviewed by a top selection committee and the top 25 best start-ups awarded.

“We are immensely honored to win another prestigious industry award and to be part of helping customers transform their monitoring practices through our technology platforms”, comments Franҫois Torche, CEO of CluePoints. “These recognitions are testament to the strength of our team, whose efforts and dedication to helping our customers access the very best technology to make clinical trials as effective as possible, is the driving factor in everything the company achieves.”

CluePoints recognized as one of Europe’s most innovative businesses in the technology sector

30 October 2014

Cambridge, MA – CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has secured an ENTENTE Life Science Investment Forum Award. The award program, which is organized by the ENTENTE project and supported by the European Commission and EuropaBio, recognized CluePoints as one of Belgium’s most innovative high technology businesses for its Central Statistical Monitoring (CSM) solution that employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.

The Belgian edition of the ENTENTE Life Science Investment Forum united 28 European early stage innovative companies, selected from a pool of 100 companies making significant advances in the health sector. The selected companies pitched their innovations and developments to an international judging panel consisting of 50 venture capitalists, corporate investors and industry experts. As a result of being selected for the Belgian ENTENTE award, CluePoints has now qualified to continue along the European Venture contest; a pan-European contest that brings together the top companies from each edition to join the European Venture Summit, taking place 8-9th December 2014 in Dusseldorf, Germany.

“This award win is another real testament to the hard work and unwavering commitment from the CluePoints team”, said Franҫois Torche, CEO of CluePoints. “We developed our monitoring solutions with a shared belief that we could make a real difference to the way that oversight is approached in clinical trials. We are absolutely delighted to have been recognized by ENTENTE for our efforts”.

For further information on CluePoints’ solutions, please visit www.CluePoints.com

About CluePoints
CluePoints® is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and to drive a risk-based monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.

Media contact
Patrick Hughes – Chief Commercial Officer, CluePoints
Patrick.Hughes@CluePoints.com
+44 (0) 7703 532 749